Reimagining Cancer Care: The Emerging Role of Circulating Tumour DNA (ctDNA) in Detection, Diagnosis and Management of Cancer

Circulating tumour DNA (ctDNA) testing is an emerging technology with the potential to transform cancer care, offering minimally invasive insights for detection, diagnosis, and disease monitoring. This IQVIA white paper reviews current evidence and implementation trends in ctDNA testing, outlining its potential across the cancer care continuum and the ongoing technical, regulatory, and reimbursement hurdles that pose barriers to clinical adoption.

Realising the promise of ctDNA testing will require concerted multi-stakeholder collaboration to establish best practice frameworks, share knowledge, and address systemic access barriers. The journey to routine ctDNA testing is ongoing, and its legacy will be a foundation for ever more precise, personalised, and effective cancer care.

Download the white paper now for more insights.

Real World Evidence

IQVIA Real World Solutions is the proven partner life science companies trust to take on their complex evidence challenges. We enable our customers to generate and disseminate real world evidence to answer crucial questions and meet the needs of their stakeholders.

Pathway Transformation

Genomics

Learn how IQVIA is unlocking genomic data, at scale, while preserving privacy. Enabling a faster, more flexible, and less expensive approach for scientific enquiry into human biology, drug discovery and drug development.

Oncology & Hematology

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Get instant access

Related solutions